ICTP marker and breast cancer with bone metastases – our experience
Authors:
V. Bella; E. Zámečníková; E. Minariková; J. Silešová; H. Danielová; E. Rácová
Published in the journal:
Prakt Gyn 2010; 14(1): 22-24
Category:
Original Article
Summary
Breast cancer is the most common cancer in the female population. In spite of much progress in diagnostics and treatment, metastases frequently occur, locoregional as well as distant. Early diagnosis of the distant metastases is sometimes problematic. Specific marker plasma level determination represents one of the options currently used for metastases detection. ICTP (carboxy‑terminal telopeptide of type- I collagen) marker is one of the newly available markers. Our outpatient clinic focused on determining the sensitivity and specificity of this marker in detecting bone metastases associated with breast cancer. We examined 138 women. The cohort consisted of asymptomatic women diagnosed with breast cancer in preventive monitoring and/ or treatment without verified metastases or increased CA 15- 3, CEA markers and of women with newly diagnosed breast cancer. With the threshold ICTP plasma level of 5.7 μmol/ ml, the sensitivity of ICTP examination was 64% and specificity 91%. The ICTP marker is one of the newly available markers that is increasingly being used in clinical practice.
Key words:
breast cancer – ICTP – carboxy‑terminal telopeptide of type- I collagen
Zdroje
1. Ailgaard N, Bentzem SM, Nielsen JL et al. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy‑terminal telopeptide of type I collagen (ICTP). Br J Haematol 1997; 96(1):103– 110.
2. Berruti A, Dogilotti L, Gorzegno G et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 1999; 45: 1240– 1247.
3. Boxer DI, Todd CE, Coleman R et al. Bone secondaries in breast cancer: the solitary metastasis. J Nucl Med 1989; 30(8): 1318– 1320.
4. Chrapko BE, Nocun A, Gołębiewska R et al. Bone turnover markers and bone scintigraphy in the evaluation of skeletal metastases. Nuclear Medicine Review 2005; 8(2): 100– 104.
5. Dose‑Schwarz J, Mahner S, Schirrmacher S et al. Detection of metastases in breast cancer patients: comparison of FDG PET with chest X‑ray, bone scintigraphy and ultrasound of the abdomen. Nuklearmedizin 2008; 47(3): 97– 103.
6. Galasko CSB. The anatomy and pathways of skeletal metastases. In Weiss L, Gilbert AH. Bone Metastase. Boston, MA: G. K. Hall, 1981: 49– 63.
7. Jakob C, Liebisch P, Egerer K et al The Bone Resorption Marker Serum- ICTP and the Circulating Proteasome Levels Separate ISS- Stages 1– 3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma. Blood 2007; 110(11), November 16.
8. Kapustzová M, Krejčí E, Vočková J. Kostní marker ICTP v diagnostice kostních metastáz. CD, SEKCAMA 2006.
9. Kapustová M, Schneiderka P, Pjajková D et al. Kostní metastázy u karcinomu prsnu. OKB a Onkologická klinika FN Olomouc (sborník abstrakt str. 111). 19.– 21. 10. 2006 Jihočeské onkologické dny.
10. Kapustová M, Cwiertka K, Minařík J et al. Význam kostního markeru – ICTP v diagnostice kostních metastáz. OKB a Onkologická klinika FN Olomouc (sborník abstrakt str. 23). 8. 12. 2006 Prediktivní a experimentální onkologie, ROC Olomouc
11. Keskikuru R, Kataja V, Kosma VM et al. Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer. Anticancer Res. 1999, Sep- Oct; 19(5C): 4481– 4484.
12. Koizumi M et al. Bone metabolic markers in the evaluation of bone scan flare phenomen in bone metastase of breast cancer. Clin Nucl Med 1999; 24(15): 15– 20.
13. Koizumi M, Yamada Y, Takiguchi T et al. Bone metabolic markers in bone metastases. J Cancer Res Clin Oncol 1995; 121: 9– 10.
14. Koizumi M, Matsumoto S, Takahashi S et al. Bone Metabolic Markers in the Evaluation of Bone Scan Flare Phenomenon in Bone Metastases of Breast Cancer. Clin Nucl Med 1999; 24(1): 15– 20.
15. Krasnow AZ, Hellman RS, Timins ME et al. Diagnostic bone scanning in oncology. Semin Nukl Med 1997; 27(2): 107– 141.
16. Kwai AH, Stomper PC, Kaplan WD. Clinical significance of isolated scintigraphic sternal lesions in patients with breast cancer. J Nucl Med 1988; 29(3): 324– 328.
17. Maemura M et al. Serum concentration of pyridinoline cross‑linked carboxyterminal
telopeptide of type I collagen in patients with metastatic breast cancer. Oncol Rep 2000; 7(6): 1333– 1338.
18. Nekulová M, Šimíčková M, Petráková K et al. N- (amino) propeptid prokolagenu 1 (P1 NP) a kostní metastázy karcinomu prsu. Sborník přednášek. Diagnostia a léčba karcinomu prsu. XIII. Jihočeské onkologické dny. Český Krumlov 19.– 21. 10. 2006, 114– 115.
19. Risteli J et al. Radioimmunoassay for the pyridinoline cross‑linked carboxyterminal telopeptide of type I collagen: A new serum marker of bone resorption. Clin Chem 1993; 39: 635– 640.
20. Sherry MM, Greco FA, Johnson DH et al. Metastatic breast cancer confined to skeletal system. An indolant disease. Am J Med 1986; 81(3): 381– 386.
21. Shimozuma K, Sonoo H, Fukunaga M et al. Biochemical markers of bone turnover in breast cancer patients with bone metastases: A preliminary report. Jpn J Clin Oncol 1999; 29(1): 16– 22.
22. St Clair EW, Moak SA, Wilkinson WE et al. A cross sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis. J Rheumatol 1998; 25(8): 1472– 1479.
23. Tähtelä R, Tholix E. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy- and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res 1996; 16(4B): 2289– 2294.
24. Tubiana- Hulin M. Incidence, prevalence and distribution of bone metastasis. Bone 1991; 12(Suppl 1): 9– 10.
25. Ylisirniö S, Höyhtyä M, Mäkitaro R et al. Elevated Serum Levels of Type I Collagen Degradation Marker ICTP and Tissue Inhibitor of Metalloproteinase (TIMP) 1. Clinical Cancer Research 2001; 7(6): 1633– 1637.
Štítky
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineČlánok vyšiel v časopise
Practical Gynecology
2010 Číslo 1
Najčítanejšie v tomto čísle
- Margin status of conizations with histological finding carcinoma in situ
- ICTP marker and breast cancer with bone metastases – our experience
- Intrahepatic cholestasis of pregnancy – selected perinatal outcomes.
- Therapeutic options for assisted reproduction in patients with impaired ovarian reserve